Mostrando 10 resultados de: 30
Filtros aplicados
Publisher
Pharmacogenomics(11)
Pharmacogenomics Journal(3)
Current Drug Targets(2)
Drug Metabolism and Drug Interactions(2)
European Journal of Clinical Pharmacology(2)
Área temáticas
Farmacología y terapéutica(23)
Enfermedades(14)
Bioquímica(12)
Fisiología humana(7)
Fisiología y materias afines(3)
Área de conocimiento
Farmacología(18)
Genética(13)
Psicopatología(5)
Medicamento(4)
Laboratorio médico(1)
High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
ArticleAbstract: Background: Interethnic differences in CYP2D6 allele frequency have been demonstrated across Latin-APalabras claves:COLOMBIA, CYP2D6, Hispanics, Mestizos, Ultrarapid metabolizersAutores:Adrián LLerena, Borbón-Orejuela A., de Andrés F., Dorado P., P Sarmiento A.Fuentes:scopusHigh-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
ArticleAbstract: Background: Aripiprazole (ARI) is an antipsychotic drug that is metabolized to dehydroaripiprazole (Palabras claves:Aripiprazole, CYP2D6, Dehydroaripiprazole, High-performance liquid chromatography, Psychiatric patientsAutores:Adrián LLerena, de Andrés F., De la Rubia A., Dorado P., Gonz Ález A., Gonz Ález I., Naranjo M.E.G., Peñ As-Lledó E.Fuentes:scopusEvaluating a newly developed pharmacogenetic array: Screening in a Spanish population
ArticleAbstract: Aims: How genes affect the response in a patient to a given medication is still poorly understood; tPalabras claves:accuracy, CYP2D6, PHARMAChip array ®, pharmacogenetics, sensitivity, SLC6A4, Specificity, successful genotyping rateAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Gomez-Dominguez B., Lopez-Rodriguez R., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusEffect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
ArticleAbstract: Sixteen hospitalized white European Spanish psychiatric patients treated with thioridazine alone werPalabras claves:CYP2D6, debrisoquine, Inhibition, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopusDetermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopus